Novartis acquisition of Morphosys receives approval from Germany
Published: Tuesday, Mar 12th 2024, 11:30
Updated At: Tuesday, Mar 12th 2024, 11:50
Retour au fil d'actualité
Novartis pourrait racheter la société allemande de biotechnologie Morphosys. L'Office allemand des cartels a donné son feu vert à cette acquisition mardi.
"We have examined very carefully that competition in the research and development of new drugs against a form of leukemia will not be impaired by the merger. As a result, we have no serious competition concerns," explained Andreas Mundt, President of the German Federal Cartel Office, in a press release.
Novartis a annoncé son intention d'acheter Morphosys au début du mois de février et compte payer 68,00 euros par action. Cela porte le prix d'achat à 2,7 milliards d'euros.
The transaction gives Novartis access to pelabresib, a drug for the treatment of myelofibrosis (MF), a life-threatening chronic disease of the bone marrow. In a recent combination study, the active ingredient led to a reduction in spleen volume and thus achieved the targets set. In the USA, the application for approval from the US Food and Drug Administration (FDA) should be submitted in the second half of 2024 if possible.
©Keystone/SDA
French 
English 
German 
Spanish 
Arabic